Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-Term Safety of Pirtobrutinib (Master Protocol)
NCT06876649Phase 4Recruiting
- Sponsor
- Eli Lilly and Company
- Start
- May 2025
- Primary completion
- May 2030
- Countries
- 8
01
Overview
Phase 4, open-label, single-arm trial of pirtobrutinib in chronic lymphocytic leukemia (CLL) and non-Hodgkin lymphoma (NHL), sponsored by Eli Lilly and Company. Primary endpoint: Percentage of Participants with a Grade ≥3 treatment-emergent AEs. Started May 2025; status: recruiting.
02
Drugs
pirtobrutinib
03
Conditions
chronic lymphocytic leukemia (CLL)non-Hodgkin lymphoma (NHL)
Beyond the preview
Go deeper on NCT06876649.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06876649.